The latest update is out from Delcath Systems (DCTH).
Delcath Systems, Inc. has released a press release on August 28, 2024, announcing promising outcomes from an independent study focused on a liver-targeted treatment for patients with uveal melanoma. This announcement could spark interest among investors, as such positive developments in the medical field often have the potential to influence a company’s stock performance. However, it is worth noting that the details provided in the release are not considered filed under securities law and are not integrated into any legal filings, except as explicitly referenced.
Find detailed analytics on DCTH stock on TipRanks’ Stock Analysis page.
